You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

March 27 2015

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

Pharma needs to refocus on what matters most

Pharmacists are often afterthoughts to the conversation, even though they are arguably the healthcare providers with more ability to influence patient outcomes and maximize the value of high-cost medication therapies than any other member of the care continuum. » Read more

FDA expands approval of aflibercept injection to treat diabetic retinopathy

FDA has expanded the approval of aflibercept (Eylea, Regeneron) injection to treat diabetic retinopathy in patients with macular edema. » Read more

Continuing Education

2015 Updates on the national guidelines for diabetes management and related disorders

Last month and this month pharmacists will be able to learn about the latest developments in diabetes treatment and management. Pharmacists can earn up to 4 hours of CPE credit with two monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics. The goal of this month's activity is to discuss the recent updates of national U.S. guidelines for diabetes management, including hypertension and cholesterol management in patients with diabetes, in order to empower pharmacists in clinical decision-making.

Read/print the article: Click here

Take the test: Click here to log in with the Session Code 15DT16-TAJ88.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

Tanezumab clinical trials to resume for chronic pain

Pfizer and Eli Lilly and Compamy said they will resume phase 3 clinical studies for tanezumab for chronic pain, after FDA lifted a partial hold on trials. » Details

POLL:

A new class of biologics in the PCSK9 Inhibitors likely will be approved for treating high cholesterol. How are you preparing?

 

RELATED ARTICLES

[BLOG]: Best Practices between formulary managers and pharmacists to address challenges in COPD readmissions

DME study: Aflibercept injection shows greater gains in visual acuity than alternative anti-VEGF therapies

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group